Aerie given lift ahead of FDA advisory panel meeting

12 October 2017

Eye disease specialist Aerie Pharmaceuticals (Nasdaq: AERI) has jumped 15% on the Nasdaq, after the US FDA released documents, ahead of an advisory meeting, in which Rhopressa (netarsudil) was deemed able to effectively reduce eye pressure.

Aerie was forced to withdraw its regulatory submission in October 2016, when it became clear the contract manufacturer wasn’t ready for a site inspection. The package was resubmitted to the US FDA in March.

A previous disappointment came in 2015, when the ROCKET 1 trial failed to show a positive efficacy comparison with twice-daily timolol, the most widely used comparator in registration trials for glaucoma.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK